• Wilms’ tumor (pediatric kidney cancer)
  • Rhabdomyosarcoma
  • Ewing’s sarcoma

Dose:

Wilms’ tumor, rhabdomyosarcoma, Ewing’s:

  • 15 mcg/kg IV daily for 5 days or 1.25 mg/m² IV every 3 weeks
  • Gestational trophoblastic neoplasia (GTN)
  • Testicular cancer (as part of multi-agent regimens)
  • Solid tumors in children and adults, often in combo regimens

Dose:

Gestational trophoblastic neoplasia (low-risk):

  • 12 mcg/kg IV daily for 5 days (alternative: single-dose 1.25 mg/m² IV every 2 weeks)
  • Vial: 500 mcg (0.5 mg) for reconstitution
  • Administered IV only (never intrathecally — fatal)
  • Reconstitute with sterile water
  • Administer via slow IV push or short infusion
  • Use central line when possible due to vesicant properties
  • Avoid extravasation — may cause severe tissue necrosis
  • Class: Cytotoxic antibiotic (antitumor antibiotic)
  • Mechanism of Action:
    • Intercalates DNA → inhibits RNA polymerase → blocks RNA and protein synthesis
    • Cell cycle non-specific
  • Half-life: ~36 hours
  • Excretion: Mainly biliary/fecal; some renal
  • Nausea/vomiting (highly emetogenic)
  • Fatigue
  • Alopecia
  • Oral mucositis/stomatitis
  • Myelosuppression (neutropenia, thrombocytopenia)
  • Known hypersensitivity
  • Concurrent live vaccines
  • Severe bone marrow suppression
  • Radiation therapy: increases risk of radiation recall
  • Other myelosuppressive drugs: additive toxicity
  • No major CYP-mediated interactions reported

                                   Drug Status

Availability
Pregnancy
Breastfeeding
Schedule
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Dacticin 0.5mg Injection 1’s Veteran Pharma Veteran Pharma